Chemotherapy of head and neck squamous cell carcinoma (HNSCC)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chemotherapy of head and neck squamous cell carcinoma of the (HNSCC) has taken a worthy place in the treatment regimens of locally advanced primary neoplastic processes, and in the treatment of relapses and distant metastases. Modern treatment regimens for locally advanced HNSCC require timely and adequate incorporation of the entire arsenal of chemotherapy effective in this type of tumors. In particular, the use of induction chemotherapy with taxanes, drugs that provide the highest locoregional control, is justified. The use of targeted therapy, including drug cetuximab, has expanded our therapeutic options in the treatment of locally advanced neoplastic processes and provides the high efficiency of 1st line chemotherapy in recurrent HNSCC and distant metastases.

Full Text

Restricted Access

About the authors

I. S Romanov

References

  1. Decker D., Drelichman A., Jacobs J., et al. Adjuvant chemotherapy with high dose bolus cisdiamminodichloroplatinum ii (CDD) and 120 hour infusion 5-fluorouracil (5-FU) in stage iii and iV squamous cell carcinoma of the head and neck. ASCO annual meeting. Saint Louis 1982;abstr 757.
  2. Browman G.P., Cronin L. Standart chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials.Semin Oncol 1994;21:311-19.
  3. Pignon J.P., Bourhis J., Domenge C., Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. Lancet 2000;355:949-55.
  4. The Department of Veterans Affairs Laryngeal Cancer Study Group. induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-90.
  5. Richard J.M., Sancho-Garnier H., Pessey J.J., et al. Randomised trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998;34:224-28.
  6. Bourhis J., Armand C., Pignon J.P. Update of the MACH-NC (meta-analysis of chemotherapy in head and neck cancer) database focused on concomitant chemoradiotherapy. Proc Am Soc Clin Oncol 2004;22:abstr 5505.
  7. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Eng J Med 2003;349:2091 -98.
  8. Weber R.S., Berkey B.A., Forastiere A., et al. Outcome of salvage total laryngectomy following organ preservation therapy: The Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg 2003;129:44-9.
  9. Forastiere A., Maor M., Weber R., et al. Long-term results of intergroup RTOG 91-11: a phase iii trial to preserve the larynx induction cisplatin/5FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proc Am Soc Clin Oncol 2006;24:abstr. 5517.
  10. Remenar E., Van Herpen C., Germa Lluch J., et al. A randomized phase iii multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil versus neoadjuvant PF in patients with locally advanced, unresectable squamous cell carcinoma of the head and neck. Final analysis of EORTC 249971. Proc Am Soc Clin Oncol 2006; abstr. 5516.
  11. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. New Engl J Med 2007;357( 17):21-31.
  12. Calais G., Pointreau Y., Alfonsi M., et al. Randomized phase iii trial comparing induction chemotherapy using cisplatinum, fluorouracil with or without docetaxel for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-01. Proc Am Soc Clin Oncol 2006; abstr. 5506.
  13. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase iii study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 3:8636-45.
  14. Cohen E.W., Karrison T., Kocherginsky M., et al. DeCiDE: A phase iii randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2012; abstr. 5500.
  15. Grandis J.R., Melhem M.F., Gooding W.E., et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl Cancer inst. 1998;90(11):824-28.
  16. Ciardiello F., Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001;7;2958-70.
  17. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354(6):567-78.
  18. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-years survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11(1):21-8.
  19. Ang K.K., Zhang Q.E., Rosenthal D.I., et al. A randomized phase iii trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage iii-iV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011;29(Suppl.):abstr. 5500.
  20. Lefebvre J., Pointreau Y., Rolland F., et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase ii TREMPLiN study. J Clin Oncol 2009;27:15s (Suppl.):abstr. 6010.
  21. Jacobs С., Lyman G., Velez-Garcia., et al. A phase iii randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck J Clin Onco. 1992;10:257-63.
  22. Forastiere A., Metch B., Schuller D.E., et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 1992; 10(8): 1245-51.
  23. Clavel M., Vermorken J.B., Cognetti F., et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase iii study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994;5:521-26.
  24. Gibson M.K., Li Y., Murphy B., et al. Randomized phase iii evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23(5):3562-67.
  25. Vermorken J.B., Mesia R., Rivera F., et al., Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359(11): 1116-27.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies